Long description:

The rapid flow of studies in the field of cancer and immunology during the last decades has increased our understanding of the interactions between the immune system and cancerous cells. In particular, it has been well-known that such interactions result in the induction of epigenetic changes in cancerous cells and the selection of less immunogenic clones as well as alterations in immune responses. Understanding the crosstalk between nascent transformed cells and cells of the immune system has led to the development of combinatorial immunotherapeutic strategies to combat cancer.

The Handbook of Cancer and Immunology offers a comprehensive and up-to-date review of cancer immunology and immunotherapy, emphasizing key findings and clinically relevant data. This reference work is an essential resource for researchers, students, academics, and clinicians committed to advancing knowledge, diagnostics, and treatments in this vital field.

Table of Contents:

T cell metabolism and its regulation by checkpoint molecules.- Tumor evasion of the immune system: the role of INF and TNF in cancer.- Intra-tumor cell heterogeneity: different immune responses for different cells.- Epithelial-mesenchymal plasticity, a link between inflammation and cancer metastasis.- Spatial technologies: a game changer to study tumor microenvironment.- Advances in tumor microenvironment immuneprofiling.- Immunodiagnostics: A perspective of tumor-specific antigen expression, specificity, and stability.- Immunohistochemistry as a tool to guide diagnosis, treatment, and prognosis in brain tumors.- Immune check point inhibitors and anti-angiogenic therapy for cancer.- Immune checkpoint inhibitors in unresectable hepatocellular carcinoma patients.- Synthetic-based Tumor-infiltrating lymphocytes (TILs) in adoptive cell therapies.- Development of next-generation antibody therapeutics using DDS and molecular imaging.- Immunotherapy for triple-negative breast cancer.- Immunotherapy for endocrine cancers.- Novel cancer treatment using oncolytic virus therapy.- Lysine acetylation inhibitors (KATi) as novel therapeutics.- CRISPR-Cas9 in personalized treatment in cancer.- Antibody-functionalized nanoparticles for targeted drug delivery in cancer therapy.- Challenges in computational pathology of biomarkers-driven predictive and prognostic immunotherapy.- Diagnosis and management of toxicities associated with immunotherapy in cancer.